Wall Street Zen Upgrades TriSalus Life Sciences (NASDAQ:TLSI) to “Hold”

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Finally, Canaccord Genuity Group upped their target price on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Hold” and an average target price of $11.00.

TriSalus Life Sciences Trading Down 0.4%

Shares of TLSI stock opened at $4.97 on Friday. TriSalus Life Sciences has a twelve month low of $3.42 and a twelve month high of $7.95. The stock has a fifty day simple moving average of $6.37 and a two-hundred day simple moving average of $5.26. The stock has a market capitalization of $248.30 million, a price-to-earnings ratio of -2.46 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The firm had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $11.76 million. Research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On TriSalus Life Sciences

Large investors have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey acquired a new stake in TriSalus Life Sciences in the 2nd quarter worth approximately $29,000. JPMorgan Chase & Co. lifted its position in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $47,000. Sequoia Financial Advisors LLC acquired a new position in shares of TriSalus Life Sciences in the third quarter valued at about $90,000. Finally, New York State Common Retirement Fund acquired a new position in shares of TriSalus Life Sciences in the second quarter valued at about $108,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.